ScreenerHero

ALXOALX Oncology Holdings Inc.

NAS · US · Healthcare · Biotechnology · alxoncology.com
2.040USD-0.97%Mkt Cap: 282.09M $P/E: —

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap282.09M $
Enterprise Value147.98M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-101.69M $
Revenue/Share—
Last Price2.040 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees48
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.70
PEG—
EV/EBITDA-1.80
EV/Revenue—
P/S—
P/B2.02
EPS (TTM)-1.11
EPS (Forward)-0.54
52W Range
0.660069% of range2.660
52W High2.660 USD
52W Low0.6600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-391.42%
ROA-172.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-84.14M $
CapEx (TTM)212.00K $
FCF Margin—
FCF Yield-14.59%
Net Debt-127.19M $
Net Debt/EBITDA1.55
Balance Sheet
Debt/Equity0.38
Current Ratio9.71
Quick Ratio9.43
Book Value/Sh0.9850 USD
Cash/Share1.000 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.600 USD
Upside (mean)+125.5%
Target Range4.000 USD – 6.000 USD
$4.000+125.5% to mean$6.000
# Analysts5
Ownership
Shares Out.138.28M
Float94.74M
Insiders0.89%
Institutions84.58%
Short Interest
Short Ratio9.1d
Short % Float6.19%
Short % Out.5.58%
Shares Short7.72M
Short (prev mo.)6.32M
Technical
SMA 501.941 (+5.1%)
SMA 2001.786 (+14.2%)
Beta0.40
S&P 52W Chg18.16%
Avg Vol (30d)910.82K
Avg Vol (10d)1.69M
Technical Indicators
RSI (14)53.4
MACD0.0131
MACD Signal0.0137
MACD Hist.-0.0006
BB Upper2.111 USD
BB Middle1.995 USD
BB Lower1.878 USD
BB Width11.69%
ATR (14)0.1331 USD
Vol Ratio (20d)0.41x